In a report released today, Timothy Ramey from Pivotal Research reiterated a Buy rating on USANA Health (USNA), with a price target of $105. The company’s shares opened today at $86.50.
Ramey noted:
“We remain bullish on the prospects for USANA. Our estimate goes to $5.30, up from $5.20 previously, our 2020 estimate which is a 53-week year, is unchanged at $6.25. We have noted that this weak 1Q would be exactly the type of event that would prompt more aggressive share repurchases – which are not built into guidance. USNA is likely to regain its double-digit top-line growth later this year, even with pressure from F/X. This is a good, innovative company that has strong growth characteristics – with the occasional hiccup. Our price target goes to $105 based on 16.8x 2020 EPS.”
According to TipRanks.com, Ramey is a 4-star analyst with an average return of 8.9% and a 57.3% success rate. Ramey covers the Consumer Goods sector, focusing on stocks such as Constellation Brands Inc, Brown-Forman B, and Flowers Foods.
USANA Health has an analyst consensus of Moderate Buy, with a price target consensus of $105, representing a 21.4% upside. In a report issued on April 16, Tigress Financial also initiated coverage with a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $137.95 and a one-year low of $75.27. Currently, USANA Health has an average volume of 217.8K.
Based on the recent corporate insider activity of 98 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, and Sense-beautiful science.
